[1]张曦,高蕾.未去除T细胞的单倍型相合造血干细胞移植的研究进展[J].第三军医大学学报,2016,38(12):1331-1339.
 Zhang Xi,Gao Lei.Research progress of haploidentical hematopoietic transplantation without T-cell depletion[J].J Third Mil Med Univ,2016,38(12):1331-1339.
点击复制

未去除T细胞的单倍型相合造血干细胞移植的研究进展(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第12期
页码:
1331-1339
栏目:
专家述评
出版日期:
2016-06-30

文章信息/Info

Title:
Research progress of haploidentical hematopoietic transplantation without T-cell depletion
作者:
张曦高蕾
第三军医大学新桥医院全军血液病中心
Author(s):
Zhang Xi Gao Lei

Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

关键词:
造血干细胞移植单倍型相合移植物抗宿主病复发
Keywords:
hematopoietic stem cell transplantation haploidentical graft-versus-host disease relapse
分类号:
R617; R733.7
文献标志码:
A
Abstract:

Human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplantation (HLA-haplo HSCT) without T-cell depletion has tremendously progressed over the past 20 years. Advances in graft manipulation, conditioning regimens, and pharmacological graft-versus-host disease (GVHD) prophylaxis have reduced the risk of fatal graft failure and severe GVHD. Donor-specific anti-HLA antibodies (DSA) negative status and killer immunoglobulin-like receptor (KIR) mismatch play potential roles in reducing the risk of graft failure and GVHD following HLA-haplo HSCT. New strategies to improve HLA-haplo HSCT outcomes include donor lymphocyte, selected T-cell subset and NK cell infusion, mesenchymal stem cell (MSC) co-transplantation and interleukin-2 application. Future challenges remain in improving post-transplant immune reconstitution and finding the best approach to reduce the incidence and severity of GVHD while simultaneously preserving the graft-versus leukemia effect to prevent the recurrence of underlying malignancy.

参考文献/References:

[1]Bashey A, Zhang X, Sizemore C A, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation[J]. J Clin Oncol, 2013, 31(10): 1310-1316.DOI: 10.1200/JCO.2012.44.3523
[2]Huang X J, Zhu H H, Chang Y J, et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission[J]. Blood, 2012, 119(23): 5584-5590.DOI: 10.1182/blood-2011-11-389809
[3]Chen  X H, Gao L, Zhang X, et al. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation[J]. Blood Cells Mol Dis, 2009, 43(1): 98-104. DOI: 10.1016/j.bcmd.2009.02.005
[4]Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculums[J]. Blood, 1994, 84(11): 3948-3955.
[5]Mulanovich V E, Jiang Y, de-Lima M, et al. Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation[J]. Am J Blood Res, 2011, 1(1): 98-105.
[6]Chen X H, Zhang C, Zhang X, et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies[J]. Biol Blood Marrow Transplant, 2009, 15(2): 266-273.DOI: 10.1016/j.bbmt.2008.11.029
[7]Bashey A, Solomon S R. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor[J]. Bone Marrow Transplant, 2014, 49(8): 999-1008.DOI: 10.1038/bmt.2014.62
[8]Lu D P, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation[J]. Blood, 2006, 107(8): 3065-3073. DOI: 10.1182/blood-2005-05-2146
[9]Chen H, Liu K Y, Xu L P, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1110-1116.DOI: 10.1016/j.bbmt.2015.02.009
[10]Gao L, Wen Q, Chen X, et al. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China[J]. Biol Blood Marrow Transplant, 2014, 20(12): 1932-1939.DOI: 10.1016/j.bbmt.2014.08.001
[11]Schuettpeltz L G, Borgerding J N, Christopher M J, et al. G-CSF regulates hematopoietic stem cell activity, in part, through activation of Toll-like receptor signaling[J]. Leukemia, 2014, 28(9): 1851-1860.DOI: 10.1038/leu.2014.68
[12]Zhang X, Li Y, Zhang Y, et al. Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China[J]. Leuk Res, 2013, 37(6): 657-664.DOI: 10.1016/j.leukres.2013.03.005
[13]Kanda J, Chao N J, Rizzieri D A. Haploidentical transplantation for leukemia[J]. Curr Oncol Rep, 2010, 12(5): 292-301.DOI: 10.1007/s11912-010-0113-4
[14]Bethge W A, Faul C, Bornhauser M, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update[J]. Blood Cells Mol Dis, 2008, 40(1): 13-19.DOI: 10.1016/j.bcmd.2007.07.001
[15]Rizzieri D A, Koh L P, Long G D, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution[J]. J Clin Oncol, 2007, 25(6): 690-697.DOI: 10.1200/JCO.2006.07.0953
[16]Federmann B, Bornhauser M, Beelen D W, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase Ⅱ study [J]. Haematologica, 2012, 97(10): 1523-1531.DOI: 10.3324/haematol.2011.059378
[17]Jun H X, Jun C Y, Yu Z X. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor [J]. Haematologica, 2004, 89(12): 1517-1524.
[18]Wang Y, Liu Q F, Xu L P, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicentre, prospective study[J]. Blood, 2015, 125(25): 3956-3962. DOI: 10.1182/blood-2015-02-627786
[19]Ziakas P D, Zervou F N, Zacharioudakis I M, et al.Graft-versus-host disease prophylaxis after transplantation: anetwork meta-analysis[J]. PLoS One, 2014, 9(12): e114735. DOI: 10.1371/journal.pone.0114735
[20]Wang Z, Shi B, Jin H, et al. Low-dose of tacrolimus favors the induction of functional CD4(t)CD25(t)FoxP3(t) regulatory T cells in solid-organ transplantation[J]. Int Immunopharmacol, 2009, 9(5): 564-569.DOI: 10.1016/j.intimp.2009.01.029
[21]Abadja F, Atemkeng S, Alamartine E, et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response[J]. Transplantation, 2011, 92(4): 396-403.DOI: 10.1097/TP.0b013e3182247b5f
[22]Physicians abstracts[J]. Bone Marrow Transplant, 2015, 50(Suppl 1): S1-S96.DOI: 10.1038/bmt.2015.27
[23]Luznik L, Fuchs E J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation[J]. Immunol Res, 2010, 47(1/3): 65-77.DOI: 10.1007/s12026-009-8139-0
[24]Kendal A R, Chen Y, Regateiro F S, et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance[J]. J Exp Med, 2011, 208(10): 2043-2053.DOI: 10.1084/jem.20110767
[25]Luznik L, O’Donnell P V, Symons H J, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide[J]. Biol Blood Marrow Transplant, 2008, 14(6): 641-650.DOI: 10.1016/j.bbmt.2008.03.005
[26]Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update[J]. Bone Marrow Transplant, 2015, 50(Suppl 2): S37-S39. DOI: 10.1038/bmt.2015.93
[27]Aversa F, Reisner Y, Martelli M F. The haploidentical option for high-risk haematological malignancies[J]. Blood Cells Mol Dis, 2008, 40(1): 8-12.DOI: 10.1016/j.bcmd.2007.07.004
[28]Cunha C, Di-Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity[J]. Blood, 2010, 116(24): 5394-5402.DOI: 10.1182/blood-2010-04-279307
[29]Sun Y, Xu L, Liu D, et al. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation[J]. Clin Microbiol Infect, 2013, 19(11): 1029-1034.DOI: 10.1111/1469-0691.12120
[30]Rizzieri D A, Koh L P, Long G D, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution[J]. J Clin Oncol, 2007, 25(6): 690-697.DOI: 10.1200/JCO.2006.07.0953
[31]Lu R N, Miao K R, Zhang R, et al. Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases[J]. Med Oncol, 2014, 31(8): 81.DOI: 10.1007/s12032-014-0081-x
[32]Kurokawa T, Ishiyama K, Ozaki J, et al. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center[J]. Int J Hematol, 2010, 91(4): 661-669. DOI: 10.1007/s12185-010-0561-5
[33]Kern K, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals[J]. J Infect Dis, 2002, 185(12): 1709-1716. DOI: 10.1086/340637
[34]Auletta J J, Lazarus H M. Immune restoration following hematopoietic stem cell transplantation: an evolving target[J]. Bone Marrow Transplant, 2005, 35(9): 835-857. DOI: 10.1038/sj.bmt.1704966
[35]Luo X H, Chang Y J, Huang X J. Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation[J]. J Immunol Res, 2014, 2014: 631951. DOI: 10.1155/2014/631951
[36]Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value[J].Blood, 2007, 110(1): 433-440. DOI: 10.1182/blood-2006-07-038687
[37]Symons H J, Leffell M S, Rossiter N D, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation[J]. Biol Blood Marrow Transplant, 2010, 16(4): 533-542. DOI: 10.1016/j.bbmt.2009.11.022
[38]Pei R, Lee J H, Shih N J, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities[J]. Transplantation, 2003, 75(1): 43-49. DOI: 10.1097/ /01.TP.0000040431.80510.98
[39]Ciurea S O, Thall P F, Milton D R, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft Failure in Hematopoietic Stem Cell Transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(8): 1392-1398. DOI: 10.1016/j.bbmt.2015.05.001
[40]Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study[J]. Bone Marrow Transplant, 2003, 31(1): 39-44. DOI: 10.1038/sj.bmt.1703779
[41]Or R, Hadar E, Bitan M, et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation[J]. Biol Blood Marrow Transplant, 2006, 12(12): 1295-1301. DOI: 10.1016/j.bbmt.2006.07.014
[42]Wang Y, Liu D H, Xu L P, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis[J]. Bone Marrow Transplant, 2012, 47(8): 1099-1104.DOI: 10.1038/bmt.2011.213
[43]Yan C H, Wang J Z, Liu D H, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors[J]. Eur J Haematol, 2013, 91(4): 304-314. DOI: 10.1111/ejh.12168
[44]Zhou X, Di-Stasi A, Tey S K, et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene[J]. Blood, 2014, 123(25): 3895-3905.DOI: 10.1182/blood-2014-01-551671
[45]Rizzieri D A, Storms R, Chen D F, et al. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2010, 16(8): 1107-1114.DOI: 10.1016/j.bbmt.2010.02.018
[46]Nguyen S, Beziat V, Norol F, et al. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation[J]. Transfusion, 2011, 51(8): 1769-1778.DOI: 10.1111/j.1537-2995.2010.03058.x
[47]Yoon S R, Lee Y S, Yang S H, et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study[J]. Bone Marrow Transplant, 2009, 45(6): 1038-1046.DOI: 10.1038/bmt.2009.304
[48]Choi I, Yoon S R, Park S Y, et al. Donor-derived natural killer cells infused after human leukocyte antigene-haploidentical hematopoietic cell transplantation: adose-escalation study[J]. Biol Blood Marrow Transplant, 2014, 20(5): 696-704.DOI: 10.1016/j.bbmt.2014.01.031
[49]Stuehler C, Mielke S, Chatterjee M, et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease[J]. Blood, 2009, 114(13): 2829-2836.DOI: 10.1182/blood-2009-06-224600
[50]Ciceri F, Bonini C, Stanghellini M T, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-Ⅱ study[J]. Lancet Oncol, 2009, 10(5): 489-500.DOI: 10.1016/S1470-2045(09)70074-9
[51]Amrolia P J, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation[J]. Blood, 2006, 108(6): 1797-1808.DOI: 10.1182/blood-2006-02-001909
[52]Vago L, Perna S K, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation[J]. N Engl J Med, 2009, 361(5): 478-488.DOI: 10.1056/NEJMoa0811036
[53]Di-Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation[J]. Blood, 2011, 117(14): 3921-3928.DOI: 10.1182/blood-2010-10-311894
[54]Ball L M, Bernardo M E, Locatelli F, et al. Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT[J]. Bone Marrow Transplant, 2008, 42(Suppl 2): S60-S66.DOI: 10.1038/bmt.2008.286
[55]Aggarwal S, Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses[J]. Blood, 2005, 105(4): 1815-1822. DOI: 10.1182/blood-2004-04-1559
[56]Lazarus H M, Koc O N, Devine S M, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients[J]. Biol Blood Marrow Transplant, 2005, 11(5): 389-398.DOI: 10.1016/j.bbmt.2005.02.001
[57]Ball L M, Bernardo M E, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation[J]. Blood, 2007, 110(7): 2764-2767.DOI: 10.1182/blood-2007-04-087056
[58]Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report[J]. Biol Blood Marrow Transplant, 2010, 16(3): 403-412. DOI: 10.1016/j.bbmt.2009.11.006
[59]Zhao X S, Wang X H, Zhao X Y, et al. Non-traditional CD4+CD25-CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation[J]. J Transl Med, 2014, 12: 187.DOI: 10.1186/1479-5876-12-187
[60]Schlegel P, Teltschik H M, Pfeiffer M, et al. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children[J]. Best Pract Res Clin Haematol, 2011, 24(3): 443-452.DOI: 10.1016/j.beha.2011.04.007
[61]Liu K Y, Chen Y H, Liu D H, et al. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation[J]. Bone Marrow Transplant, 2008, 42(8): 535-539.DOI: 10.1038/bmt.2008.208
[62]Kasamon Y L, Luznik L, Leffell M S, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome[J]. Biol Blood Marrow Transplant, 2010, 16(4): 482-489.DOI: 10.1016/j.bbmt.2009.11.011

更新日期/Last Update: 2016-06-07